New Findings on Cytisinicline Treatment for Quitting E-Cigarettes, with Nancy Rigotti, MD

A recent multisite randomized clinical trial known as ‘ORCA-V1 was conducted, with its investigators treating 160 adults who used nicotine e-cigarettes (vaping) but not cigarettes for 12 weeks with either a placebo or cytisinicline, a plant-based alkaloid designed to reduce nicotine dependence through the targeting of nicotinic acetylcholine receptors. Both the treatment and placebo cohorts had also been given behavioral support.
Nancy A. Rigotti, MD, one of the trial investigators, spoke with the HCPLive staff about her team’s findings. She expressed that the treatment was well tolerated and led to substantially more continuous abstinence from vaping compared to placebo. In this interview, Rigotti highlighted these findings and more regarding the product.
“Cytisinicline is this new product that we have that is being developed in the United States for smoking cessation,” Rigotti said. “It's not FDA-approved at this point but it has been available for decades as a consumer product in eastern and central Europe…So it's widely used, but it's not available in the US and it works in the same way as Chantix does in the brain to help make help cure nicotine addiction, and make it easier for people to stop whatever way they're getting nicotine.”
Read more: www.hcplive.com/view/new-find...